Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose naltrexone in ME/CFS
NCT02965768Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2016
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
Randomised, double-blind trial in myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS) comparing LDN arm with Placebo/LDN arm (2 arms). Primary endpoint: Reduction in plasma inflammatory biomarkers at 12 weeks. Planned start Jan 2016; status: withdrawn.
02
Drugs
naltrexone
03
Conditions
myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS)
Beyond the preview
Go deeper on NCT02965768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02965768.